Standard BioTools(NASDAQ) FLDM

Standard BioTools Inc. helps biomedical researchers develop better therapeutics faster. The company makes tools that analyze cells and proteins in detail. Scientists use these products to find new ways to treat diseases.

What Is in the Toolbox?

• Proteomics Platforms: CyTOF technology uses metal-tagged antibodies and mass spectrometry to analyze many components of a single cell at once.
• Spatial Biology Tools: The Hyperion system allows researchers to see how cells are organized in tissue while performing molecular and proteomic analysis.
• High-Throughput Genomics: Biomark X9 systems allow laboratories to perform rapid genetic testing and quantitative polymerase chain reaction applications.
• Consumable Supplies: Specialized reagents and kits required to run the company's instruments across its various technology platforms.

Strategic Shifts and New Directions

• Entered a merger agreement with Treeline Biosciences on June 6, 2026, to combine the two companies in an all-stock transaction.
• Sold the SomaScan proteomics business to Illumina on Jan. 30, 2026, for $388.2 million in net cash consideration.
• Consolidated research and development operations into a Singapore facility during 2025 to co-locate with manufacturing and improve efficiency.
• Relocated corporate headquarters to Boston, Massachusetts, following a 20% reduction in the global workforce during late 2025.

Why Scientists Choose These Platforms

The company provides multi-omic capabilities that allow scientists to explore biological networks and disease mechanisms with high precision. Its technologies support essential research at top biopharmaceutical companies and leading academic universities worldwide.

A Look at the Numbers

• Total revenue was $20.1 million for the three months ended June 30, 2026, down 8% year over year.
• Research and development expenses were $2.0 million for the three months ended June 30, 2026, down 68% year over year.
• Selling, general, and administrative expenses were $16.4 million for the three months ended June 30, 2026, down 42% year over year.
• Cash, cash equivalents, and investments totaled $544.0 million as of June 30, 2026.
• Net income was $100.3 million for the six months ended June 30, 2026, primarily due to the gain from selling the SomaScan business.

Bottom Line

Standard BioTools is transitioning from a specialized tools provider toward becoming a biotechnology holding company through its merger with Treeline. This evolution combines its established base of research technologies with a new strategic focus on therapeutic development.